e8vk
Table of Contents

 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES AND EXCHANGE ACT OF 1934
August 9, 2005 (August 9, 2005)
Date of Report (Date of earliest event reported)
 
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other Jurisdiction
of Incorporation) 		  000-28782
(Commission File Number) 		  93-0979187
(IRS Employer
Identification Number)
     
157 Technology Drive
Irvine, California
(Address of principal executive offices) 		  92618
(Zip Code)
(949) 788-6700
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 2.02. Results of Operations and Financial Condition.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
EXHIBIT 99.1

Table of Contents

Item 2.02.  Results of Operations and Financial Condition.
     On August 9, 2005, we issued a press release, which sets forth our results of operations for the quarter ended June 30, 2005. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.  Financial Statements and Exhibits.
     
(c)
  Exhibits
     
Exhibits:
  Description of Document
 
   
99.1
  Press Release dated August 9, 2005.
SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 9, 2005
         
  SPECTRUM PHARMACEUTICALS, INC.
 		  
  By:   /s/ Rajesh C. Shrotriya    
  Name: Rajesh C. Shrotriya    
  Title: Chairman, Chief Executive Officer and President  
 

 

Table of Contents

EXHIBIT INDEX
     
Exhibits:
  Description
 
   
99.1
  Press Release dated August 9, 2005.